Starmer Heather M, Ishman Stacey L, Flint Paul W, Bhatti Nasir I, Richmon Jeremy, Koch Wayne, Webster Kimberly, Tufano Ralph, Gourin Christine G
Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University, Baltimore, MD 21287, USA.
Arch Otolaryngol Head Neck Surg. 2009 Nov;135(11):1165-9. doi: 10.1001/archoto.2009.168.
To assess the effect of primary treatment on tracheoesophageal voice prosthesis (TEP) complications.
Retrospective cohort study.
The Johns Hopkins Medical Institutions, Baltimore, Maryland.
Patients who underwent total laryngectomy and TEP between January 1, 1998, and December 31, 2008, were divided into 3 subgroups according to primary treatment: surgery (n = 81), radiotherapy (n = 61), and chemoradiotherapy (n = 32).
Number of weeks before leakage through the TEP, occurrence of leakage around the TEP, TEP dislodgement, and size changes 6 months or longer after laryngectomy.
A total of 174 patients met the study criteria. Of the 81 patients who underwent primary surgery, 81% (n = 66) underwent adjuvant therapy with postoperative radiotherapy or chemoradiotherapy. The incidence of leakage around the prosthesis, prosthesis dislodgement, and size changes 6 months or longer after laryngectomy were significantly higher for patients who required salvage total laryngectomy after chemoradiotherapy or radiotherapy (P < .05). In addition, significantly more patients who underwent salvage total laryngectomy required extended laryngectomy or free tissue reconstruction.
Voice prosthesis complications are more frequently encountered in those who require salvage laryngectomy. Understanding the potential for such complications reinforces the need for close communication and follow-up with these patients by the speech language pathologist.
评估初始治疗对气管食管发音假体(TEP)并发症的影响。
回顾性队列研究。
马里兰州巴尔的摩市约翰霍普金斯医疗机构。
1998年1月1日至2008年12月31日期间接受全喉切除术和TEP植入的患者,根据初始治疗方法分为3个亚组:手术组(n = 81)、放疗组(n = 61)和放化疗组(n = 32)。
TEP出现渗漏前的周数、TEP周围渗漏的发生情况、TEP移位以及喉切除术后6个月或更长时间的尺寸变化。
共有174例患者符合研究标准。在81例接受初始手术的患者中,81%(n = 66)接受了术后放疗或放化疗的辅助治疗。对于放化疗或放疗后需要挽救性全喉切除术的患者,假体周围渗漏、假体移位以及喉切除术后6个月或更长时间尺寸变化的发生率显著更高(P < .05)。此外,接受挽救性全喉切除术的患者中,需要扩大喉切除术或游离组织重建的患者明显更多。
需要挽救性喉切除术的患者更容易出现发音假体并发症。了解此类并发症的可能性强化了言语病理学家与这些患者密切沟通和随访的必要性。